Illumina Inc. (ILMN) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Illumina Inc. (ILMN)

207.27

-3.79 (1.80%)

as of Sep 9, 2026, 6:21:55 pm Market Open.

47 watching

Investor Insights

Sep 9, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

Illumina Inc. (ILMN-Q) is regarded as a dominant player in the field of genomic sequencing, with strong backing from industry demand for personalized medicine. Experts highlight its impressive technology and equipment that serve as the foundation for genomic sequencing applications. The growing interest in personalized medicine, as exemplified by companies like Moderna, underlines the relevance and potential of Illumina's offerings. Analysts believe that there is ample growth opportunity ahead, positioning Illumina as a leading force in advancing genomic technologies. The overall sentiment suggests optimism about the company's future, indicating that it can continue to thrive in an evolving healthcare landscape.

Consensus

Bullish

Valuation

Undervalued

Similar

BionanoGenomics, BNGO

TOP PICK

They are a provider of sequencing solutions for genetic analysis. It is a really good entry level. It is a pretty volatile stock. Commercial genetic testing is going to explode and these guys are emphasizing consumables. (Analysts’ price target is $321.79)

PAST TOP PICK

(A Top Pick Jul 18/18, Up 15%) They analyze genetic material. We are in the early stages of doing this for a whole host of applications. They are a generation ahead of competitors. This is a technology that is still relatively new.

TOP PICK

The DNA revolution has recently started. DNA sequencing has come from the thousands of dollars to the hundreds making it ore retail. Fast growing US name. (Analysts’ price target is $345.93)

TOP PICK

He is a big believer in disrupter companies in growth sectors. This is the only company in the world that can do high volume DNA sequencing. They already have a million customers and another million order backlog. There is no one else in this space. They sell equipment and the supplies to operate the equipment. Countries will have more DNA sequencing done to help new drug development. Yield 0%. (Analysts’ price target is $286.06)

COMMENT

Dominant player in gene sequencing business. Becoming more commercially available to clinics instead of just research labs. They are buying up some of their customers and going into competition with them. He is nervous of the valuation. It is at and beyond his expectations.

Showing 16 to 20 of 20 entries

Most Recent Experts

Eric Nuttall

Ninepoint Partners

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Kevin Simpson

Capital Wealth Planning

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Illumina Inc. (ILMN)